Amgen Reports Q2 Net Profit of $746 Million, Down 45.90% Year-over-Year

Amgen Announces Financial Results: Net Profit in Q2 at $7.46 Billion, Down 45.90% YoY; Revenue at $83.33 Billion, Up 19.90% YoY; Basic Earnings Per Share at $1.39. Currently, 22 institutions have made predictions on Amgen's target price, with an average target price of $324.34, the lowest at $180.00, and the highest at $381.00. Amgen is a biotech giant with flagship drugs including Epogen and Aranesp for red blood cell enhancement, and Enbrel and Otezla for inflammatory diseases. (Sina Finance)Original Link